Clinical Trial Update: A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases [Phase 3]

View source ↗

Summary

This clinical trial update reports on the long-term safety study of TAK-881 in individuals with primary immunodeficiency diseases, currently in Phase 3 and not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• TAK-881

Snippet

Sponsor: Takeda | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 3 | Status: ACTIVE_NOT_RECRUITING